(NASDAQ:VVUS) to report earnings on August ... Insiders own 0.24% of the company's stock. Next Financial Group Inc reported 4,257 shares. Apriem Advsr has 0% invested in VIVUS, Inc. The company has market cap of $1.50 billion. The …
The stock decreased 0.14% or $0.18 on August 11, reaching $127.44. About 20 shares traded. Among 2 analysts covering Vivus (NASDAQ:VVUS), 2 have Buy rating, 0 Sell and 0 Hold. As per Friday, April 15, the company rating was …
VIVUS Inc. (VVUS - Free Report) reported a loss of 13 cents per share ... In fact, so far this year, VIVUS shares have underperformed the industry. The stock fell 11.3% during the period, while the industry witnessed a gain of 8.9%. …
Last month, VVUS shares sank sharply after the company’s stock rating was downgraded by Piper Jaffray. VVUS stock closed at $4.67 per share on Tuesday.
Campbell, CA-based VIVUS, Inc. VVUS is a biopharmaceutical company developing and commercializing ... for erectile dysfunction (ED). The stock sports a Zacks Rank #1 (Strong Buy) and looks like a good investment now. You can see …
NASDAQ3mon
In that article we said the following regarding VVUS stock: VVUS is currently range-bound between the 50-day and 200-day exponential moving averages. If a run-up in VVUS is to occur ahead of the EU approval decision, look for the stock price …
VIVUS, Inc. (NASDAQ:VVUS) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday, July 4th. According to Zacks, “VIVUS' Qsymia is the first weight-loss drug to receive …
Breeze1mon
About 253,164 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 7.14% since August 10, 2016 and is …
The Chief Medical Officer now owns $82,181 of the stock as recorded in a recent Form 4 SEC filing. Santosh T. Varghese, Chief Medical Officer reported the sale of 710 shares of VVUS stock. The shares were purchased at an average price of …